Miglustat - CAS 72599-27-0
Catalog number:
72599-27-0
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C10H21NO4
Molecular Weight:
219.28
COA:
Inquire
Targets:
Others
Description:
Miglustat is an inhibitor of the ceramide-specific glycosyltransferase, which catalyzes the first step of glycosphingolipid biosynthesis and is currently approved for the oral treatment of type I Gaucher disease (GD1).
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
N-Butyldeoxynojirimycin; NB-DNJ; OGT918; Zavesca
MSDS:
Inquire
1.Prevention of renal damage caused by Shiga toxin type 2: Action of Miglustat on human endothelial and epithelial cells.
Girard MC1, Sacerdoti F1, Rivera FP1, Repetto HA2, Ibarra C1, Amaral MM3. Toxicon. 2015 Oct;105:27-33. doi: 10.1016/j.toxicon.2015.08.021. Epub 2015 Aug 31.
Typical hemolytic uremic syndrome (HUS) is responsible for acute and chronic renal failure in children younger than 5 years old in Argentina. Renal damages have been associated with Shiga toxin type 1 and/or 2 (Stx1, Stx2) produced by Escherichia coli O157:H7, although strains expressing Stx2 are highly prevalent in Argentina. Human glomerular endothelial cells (HGEC) and proximal tubule epithelial cells are very Stx-sensitive since they express high levels of Stx receptor (Gb3). Nowadays, there is no available therapy to protect patients from acute toxin-mediated cellular injury. New strategies have been developed based on the Gb3 biosynthesis inhibition through blocking the enzyme glucosylceramide (GL1) synthase. We assayed the action of a GL1 inhibitor (Miglustat: MG), on the prevention of the renal damage induced by Stx2. HGEC primary cultures and HK-2 cell line were pre-treated with MG and then incubated with Stx2. HK- 2 and HGEC express Gb3 and MG was able to decrease the levels of this receptor.
2.Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients.
Smid BE1, Ferraz MJ2, Verhoek M3, Mirzaian M2, Wisse P4, Overkleeft HS4, Hollak CE1, Aerts JM5,6. Orphanet J Rare Dis. 2016 Mar 24;11(1):28. doi: 10.1186/s13023-016-0413-3.
BACKGROUND: We retrospectively compared biochemical responses in type 1 Gaucher disease patients to treatment with glycosphingolipid synthesis inhibitors miglustat and eliglustat and ERT.
3.Normalisation of brain spectroscopy findings in Niemann-Pick disease type C patients treated with miglustat.
Sedel F1,2, Chabrol B3, Audoin B4, Kaphan E5, Tranchant C6, Burzykowski T7, Tourbah A8, Vanier MT9, Galanaud D10. J Neurol. 2016 Mar 16. [Epub ahead of print]
Niemann-Pick disease type C (NP-C) is a fatal progressive neurolipidosis involving neuronal storage of cholesterol and gangliosides. Miglustat, an inhibitor of glycosphingolipid synthesis, has been approved to treat neurological manifestations in adults and children with NP-C. This open-label observational study in adults with confirmed NP-C evaluated the efficacy of miglustat (200 mg t.i.d.) based on composite functional disability (CFD) scores and brain proton magnetic resonance spectroscopy (H-MRS) measurement of choline (Cho)/N-acetyl aspartate (NAA) ratio in the centrum ovale. Overall, 16 patients were included and received miglustat for a mean period of 30.6 months: 12 continued on miglustat throughout follow up, and 4 discontinued miglustat because of adverse effects (n = 2) or perceived lack of efficacy (n = 2). In the 'continued' subgroup, the mean (SD) annual progression of CFD scores decreased from 0.75 (0.94) before treatment to 0.
4.Urinary excretion and metabolism of miglustat and valproate in patients with Niemann-Pick type C1 disease: One- and two-dimensional solution-state (1)H NMR studies.
Probert F1, Ruiz-Rodado V1, Zhang X2, te Vruchte D3, Claridge TD4, Edgar M5, Tocchio AZ1, Lachmann RH6, Platt FM3, Grootveld M7. J Pharm Biomed Anal. 2016 Jan 5;117:276-88. doi: 10.1016/j.jpba.2015.08.011. Epub 2015 Aug 13.
Niemann-Pick type C1 (NP-C1) disease is a neurodegenerative lysosomal storage disease for which the only approved therapy is miglustat (MGS). In this study we explored the applications and value of both one- and two-dimensional high-resolution NMR analysis strategies to the detection and quantification of MGS and its potential metabolites in urine samples collected from NP-C1 disease patients (n=47), and also applied these techniques to the analysis of the anticonvulsant drug valproate and one of its major metabolites in ca. 30% of these samples (i.e. from those who were also receiving this agent for the control of epileptic seizures). A combination of high-resolution 1D and 2D TOCSY/NOESY techniques confirmed the identity of MGS in the urinary (1)H NMR profiles of NP-C1 patients treated with this agent (n=25), and its quantification was readily achievable via electronic integration of selected 1D resonance intensities. However, this analysis provided little or no evidence for its metabolism in vivo, observations consistent with those acquired in corresponding experiments performed involving an in vitro microsomal system.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 1195-16-0 DL-N-Acetylhomocysteine thiolactone

DL-N-Acetylhomocysteine thiolactone
(CAS: 1195-16-0)

DL-N-Acetylhomocysteine thiolactone, an amino acid cysteine derivative, could be used against some liver diseases.

CAS 548-83-4 Galangin

Galangin
(CAS: 548-83-4)

Galangin is a flavonoid naturally found in herbs acts as an agonist/antagonist of the arylhydrocarbon receptor, and also shows inhibition of CYP1A1 activity.

CAS 4382-63-2 PFK15

PFK15
(CAS: 4382-63-2)

PFK15 is a potent and selective 6-phosphofructo-2-kinase (PFKFB3) with IC50 of 207 nM.

CAS 42228-92-2 Acivicin

Acivicin
(CAS: 42228-92-2)

Acivicin is a glutamine analog that irreversibly inhibits glutamine-dependent amidotransferases involved in nucleotide and amino acid biosynthesis (Kis = 10 and...

AMZ30
(CAS: 1313613-09-0)

AMZ30, a PME-1 inhibitor, could inhibit PME-1 irreversiblely and be significant in the pharmacological study of determinating the demethylated PP2A function. IC...

EL-102
(CAS: 1233948-61-2)

EL102, a HIF1α inhibitor, has been found to have potential effect in restraining polymerisation of tubulin and influencing the stability of microtubule. IC50: 2...

Crustacean Cardioactive Peptide CCAP

Crustacean Cardioactive Peptide (CCAP), originally identified in the pericardial organs of the shore crab, Carcinus means, is a highly conserved, amidated cycli...

GSK-484
(CAS: 1652591-81-5)

GSK-484, a benzoimidazole derivative, has been found to be an effective reversible PAD-4 inhibitor that could be significant in some inflammation and immune res...

CAS 3416-24-8 D-Glucosamine (Free Base)

D-Glucosamine (Free Base)
(CAS: 3416-24-8)

An amino sugar, part of the structure of the polysaccharides chitosan and chitin, is made naturally in the form of glucosamine-6-phosphate, and is the biochemic...

CAS 477-90-7 Bergenin

Bergenin
(CAS: 477-90-7)

Bergenin is trihydroxybenzoic acid glycoside and the C-glycoside of 4-O-methyl gallic acid.It shows a potent immunomodulatory effect.

CAS 522-12-3 Quercitrin

Quercitrin
(CAS: 522-12-3)

Quercitrin is a natural compound extracted from Tartary buckwheat has antiproliferative and apoptotic effects on colon cancer cells.

CAS 58-86-6 Xylose

Xylose
(CAS: 58-86-6)

D-Xylose, a natural product, is used in diagnostic malabsorption tests as well as in the production of Furfural.

FR-182024
(CAS: 179034-83-4)

FR-182024, an azabicyclo derivative, has been found to have potential activity as an anti-Helicobacter pylori agent and was once stuied against helicobacter inf...

CAS 107538-05-6 Dexmecamylamine

Dexmecamylamine
(CAS: 107538-05-6)

Dexmecamylamine is a nicotinic channel modulator with antidepressant activity. It demonstrated positive effects in a number of animal models of depression and a...

GNE-495
(CAS: 1449277-10-4)

GNE-495 is a Selective MAP4K4 (Mitogen-activated protein kinase kinase kinase kinase 4) Inhibitor. IC50 value is 3.7 nM. GNE-495 shows excellent potency and goo...

CAS 1821428-35-6 AZD0156

AZD0156
(CAS: 1821428-35-6)

AZD0156 is an orally active, potent and selective ataxia telangiectasia mutated (ATM) kinase inhibitor, used for cancer treatment. AZD0156 prevents DNA damage c...

FR 121196
(CAS: 133920-65-7)

FR 121196 is a potential antidementia drug originated by Fujisawa. Mechanism of Action is not undefined. FR 121196 can ameliorate the impaired memory of rat in ...

CAS 452-35-7 Ethoxzolamide

Ethoxzolamide
(CAS: 452-35-7)

Ethoxzolamide is used in the treatment of glaucoma, and is also used as a diuretic, acting as a carbonic anhydrase inhibitor.

CI 924
(CAS: 79520-77-7)

CI 924 is hypolipidemic agent. It can elevate anti-atherogenic HDL and lower VLDL.

CAS 56-04-2 Methylthiouracil

Methylthiouracil
(CAS: 56-04-2)

Methylthiouracil is an antithyroid preparation.The drug acts to decrease the formation of stored thyroid hormone, as thyroglobulin in the thyroid gland.

Chemical Structure

CAS 72599-27-0 Miglustat

Quick Inquiry

Verification code

Featured Items